Abstract:Given past experience with widespread viral infections, for example influenza, we expected that SARS-CoV-2 would create a large number of de novo cases of immune thrombocytopenia (ITP). Perhaps a silver lining on the cloud of SARSCoV-2 is that for patients with ITP, the virus is not having a major effect, as evidenced by few reports of ITP in conjunction with SARS-CoV-2 infection. We performed a retrospective review of patients ≥18 years diagnosed with COVID-19 and ITP seen at New York Presbyterian–Weill Cornell Medicine (NYP-WCM) or Shandong Provincial Chest Hospital–Shandong University (SPCH-SDU) from February to August 2020. Ten patients from NYPWCM and two from SPCH-SDU were identified (Table I). The study was approved by the Institutional Review Board of NYP-WCM and the Medical Ethical Committee of SPCHSDU. There were 10 patients with pre-existing ITP and two with presumed new SARS-CoV-2-associated ITP (Table I). Patient 8 was diagnosed with ITP during hospitalization for COVID19 and Patient 10 developed isolated ITP six weeks following SARS-CoV-2 infection; neither had a prior history of thrombocytopenia. For those with pre-existing ITP, SARS-CoV-2 infections were managed as outpatients (n = 3), ER visits (n = 2), and hospitalizations (n = 5). During active COVID-19, five patients required ITP treatment for platelet nadirs of 8–33 9 10/l. Patient 7 received platelet transfusion, steroids and intravenous immunoglobulin (IVIg). Patients 1 and 9 received IVIg alone. Patient 1 had been on weekly romiplostim, twice daily mycophenolate mofetil (MMF) and IVIg as needed since 2017. She had fevers, fatigue, body aches and was ITP-Bleeding Assessment Tool: Skin 1 (petechiae), Mucosae 1 (epistaxis). Due to morbid obesity, limited mobility, and advanced age, she received weekly home infusions of IVIg 80 g for counts <10– 20 9 10/l. Patient 9, on prednisone 15 mg daily for platelets 20–30 9 10/l, was hospitalized at SPCH-SDU. He received IVIg 10 g daily for two days with platelet improvement from 18 to 28 9 10/l. Patient 8 received inpatient IVIg 15 g daily for three days, methylprednisolone 80 mg BID, and convalescent plasma for SARS-CoV-2-associated ITP with platelets increasing from 33 to 83 9 10/l. Several weeks following SARS-Cov-2 diagnosis, Patient 10 received IVIg with steroids for de novo ITP with platelet improvement from 6 to 82 9 10/l. Patient 7 had chronic ITP with platelets of 8 9 10/l requiring platelet transfusions. In the setting of multiorgan failure, he declined additional treatment and passed away. Two patients received steroids alone for exacerbations of known ITP during infection with SARS-CoV-2. Patient 11’s platelets dropped from 60–70 to 23 9 10/l two weeks after diagnosis. His platelets improved to 180 9 10/l on prednisone 20 mg daily. Patient 4’s platelets dropped from a baseline of 60–70 to 26 9 10/l. She received dexamethasone 40 mg for four days with platelets rising to 105 9 10/l. Five patients (Patients 2, 3, 5, 6, 12) did not modify their ITP treatment despite COVID-19. Three (Patients 2, 3, 6) were on treatment (eltrombopag, steroids, rituximab, respectively). Patient 5 was discharged from the ER with haematology follow-up for platelets 26 9 10/l and Patient 12 was diagnosed with SARS-Cov-2 on routine screening for caesarean section with platelets 94 9 10/l. Patients 3, 4, 6, 8 were hospitalized and received prophylactic anticoagulation with enoxaparin 40 mg SC daily (NYPWCM) or nadroparin 3 800 U SC daily (SPCH-SDU) without bleeding events. Patient 6 developed deep vein thrombosis (DVT) and pulmonary embolus (PE) despite prophylactic enoxaparin. He received therapeutic heparin and was discharged on apixaban. Patient 2 presented with a new headache due to cerebral venous sinus thrombosis and was discharged on apixaban. Treatments of ITP, ongoing or newly initiated, can impact the course and outcome of SARS-CoV-2. Thrombosis is a major concern in patients with SARS-CoV-2 infection and immunosuppression could worsen infection. The American Society of Hematology offers recommendations limited by data to expert opinion for ITP management in SARS-CoV-2 infection. IVIg is not immunosuppressive, rapidly increases platelets, and has anti-inflammatory effects. To avoid prolonged visits and SARS-CoV-2 exposures, home administration (like Patient 1) is useful. Steroids may risk increasing viral susceptibility early in infection; however, published reports and our own experience suggest steroid use does not often lead to worse outcomes in COVID-19. No consensus exists regarding increased severity of COVID-19 infection in patients who have received rituximab or are on other chronic immunosuppressants. Anti-CD20 agents impair humoral responses to de novo infections and vaccines for at least 4–6 months. We agree with avoiding immunosuppressives or rituximab during the COVID-19 pandemic pending reasonable alternatives. We also caution use of splenectomy due to increased thrombotic risk and risk of overwhelming sepsis. correspondence

Protective effects of COVID‐19 vaccination in splenectomized patients with immune thrombocytopenia

Outcome and Efficacy of Laparoscopic Splenectomy in Treatment of Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenia During the COVID‐19 Pandemic

Splenomegaly and Response to Splenectomy in Immune Thrombocytopenia

Challenges in treating primary immune thrombocytopenia patients undergoing COVID-19 vaccination: A retrospective study

Factors Associated with the Effect of Open Splenectomy for Immune Thrombocytopenic Purpura.

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Decreased Levels of Immune-Regulatory Cytokines in Patients with Immune Thrombocytopenia and Long-Lasting Overexpression of These Cytokines in the Splenectomized Patients

Predictive factors associated with long-term effects of laparoscopic splenectomy for chronic immune thrombocytopenia

Clinical factors and outcomes of spleen-conserving surgery versus total splenectomy in splenic injuries: A nationwide database study

Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment

Value of Splenectomy in Treating Autoimmune Hematological Diseases

[Effects of Splenectomy on Patients Undergoing Liver Transplantation].

COVID-19-induced immune thrombocytopenia management approach: A case report and literature review

Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine

The Evolution of Preexisting Primary Immune Thrombocytopenia after COVID-19 Onset: A Nationally Representative, Prospective, Multicentre, Observational Study

Splenectomy provides protective effects against CLP-induced sepsis by reducing TRegs and PD-1/PD-L1 expression

Preventive use of low molecular weight heparin in portal vein system thrombosis after splenectomy without portal hypertension

Impact of splenectomy on the prognosis and immune function of advanced colon carcinoma undergoing palliative resection

Laparoscopic splenectomy for immune thrombocytopenia (ITP) patients with platelet counts lower than 1 × 109/L

Evaluating the Effectiveness of Laparoscopic Removal of an Accessory Spleen After a Failed Splenectomy for Immune Thrombocytopenia